Up-regulation of the D1 Dopamine Receptor–Interacting Protein, Calcyon, in Patients With Schizophrenia
BACKGROUND The dopamine hypothesis remains a prominent influence on research into the pathogenesis of schizophrenia, yet the presence of consistent schizophrenia-linked abnormalities in the presynaptic components of the dopamine system or in dopamine receptors still remains a matter of debate. The p...
Gespeichert in:
| Veröffentlicht in: | Archives of general psychiatry 2003-03, Vol.60 (3), p.311-319 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 319 |
|---|---|
| container_issue | 3 |
| container_start_page | 311 |
| container_title | Archives of general psychiatry |
| container_volume | 60 |
| creator | Koh, Phil Ok Bergson, Clare Undie, Ashiwel S Goldman-Rakic, Patricia S Lidow, Michael S |
| description | BACKGROUND The dopamine hypothesis remains a prominent influence on research into the pathogenesis of schizophrenia, yet the presence of consistent schizophrenia-linked abnormalities in the presynaptic components of the dopamine system or in dopamine receptors still remains a matter of debate. The present study focuses on a recently recognized group of dopamine receptor–interacting proteins as possible novel sites of dysfunction in schizophrenia. Specifically, we examined whether the D1 dopamine receptor–interacting protein calcyon and the D2 dopamine receptor–interacting proteins filamin-A and spinophilin are affected in the dorsolateral prefrontal cortex of patients with schizophrenia. METHODS Slot blots of dorsolateral prefrontal cortical tissue were used to compare the levels of the 3 proteins of interest in control, schizophrenic, bipolar, and major depression groups (n = 15 per group). The nonschizophrenic psychiatric groups were included to determine the specificity of the detected abnormalities. RESULTS The dorsolateral prefrontal cortex in schizophrenic patients displayed nearly twice the normal levels of calcyon, whereas filamin-A and spinophilin levels were unaltered. Patients with bipolar disorder or major depression showed no changes in all 3 proteins examined. CONCLUSION Our findings provide the first evidence that abnormalities in the dopamine system of patients with schizophrenia may lie in altered levels of dopamine receptor–interacting proteins.Arch Gen Psychiatry. 2003;60:311-319--> |
| doi_str_mv | 10.1001/archpsyc.60.3.311 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73076852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>207287</ama_id><sourcerecordid>73076852</sourcerecordid><originalsourceid>FETCH-LOGICAL-a388t-3504b6dda2b62c391ef462b22d5c4e3f6b669d39e602577681b4cc15a099a7b73</originalsourceid><addsrcrecordid>eNpFkc1u1DAURi0EotPCA3SDvIEVGfyTOMkSTaFUqkQFVLCzbpybxiixU9uzmK76DrwhT4KrmdKV79U937c4JuSUszVnjH-AYMYl7sxasbVcS86fkRWvZFNIJdVzsmKMyaJt2a8jchzj77yySomX5IgLJYRS1YqM10sR8GY7QbLeUT_QNCI94_TMLzBbh_QbGlySD3_v_1y4hAFMsu6GXgWf0Lr3dAOT2fk8WEevcgu6FOlPm0b63Yz2zi9jQGfhFXkxwBTx9eE9IdefP_3YfCkuv55fbD5eFiCbJhWyYmWn-h5Ep4SRLcehVKIToq9MiXJQnVJtL1tUTFR1rRrelcbwCljbQt3V8oS82_cuwd9uMSY922hwmsCh30ZdS5ZTlcgg34Mm-BgDDnoJdoaw05zpB736Ua9WTEud9ebMm0P5tpuxf0ocfGbg7QGAaGAaAjhj4xNXqjJ_Qpm50z0HM_y_ClaLppb_AMkTjl0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73076852</pqid></control><display><type>article</type><title>Up-regulation of the D1 Dopamine Receptor–Interacting Protein, Calcyon, in Patients With Schizophrenia</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Koh, Phil Ok ; Bergson, Clare ; Undie, Ashiwel S ; Goldman-Rakic, Patricia S ; Lidow, Michael S</creator><creatorcontrib>Koh, Phil Ok ; Bergson, Clare ; Undie, Ashiwel S ; Goldman-Rakic, Patricia S ; Lidow, Michael S</creatorcontrib><description>BACKGROUND The dopamine hypothesis remains a prominent influence on research into the pathogenesis of schizophrenia, yet the presence of consistent schizophrenia-linked abnormalities in the presynaptic components of the dopamine system or in dopamine receptors still remains a matter of debate. The present study focuses on a recently recognized group of dopamine receptor–interacting proteins as possible novel sites of dysfunction in schizophrenia. Specifically, we examined whether the D1 dopamine receptor–interacting protein calcyon and the D2 dopamine receptor–interacting proteins filamin-A and spinophilin are affected in the dorsolateral prefrontal cortex of patients with schizophrenia. METHODS Slot blots of dorsolateral prefrontal cortical tissue were used to compare the levels of the 3 proteins of interest in control, schizophrenic, bipolar, and major depression groups (n = 15 per group). The nonschizophrenic psychiatric groups were included to determine the specificity of the detected abnormalities. RESULTS The dorsolateral prefrontal cortex in schizophrenic patients displayed nearly twice the normal levels of calcyon, whereas filamin-A and spinophilin levels were unaltered. Patients with bipolar disorder or major depression showed no changes in all 3 proteins examined. CONCLUSION Our findings provide the first evidence that abnormalities in the dopamine system of patients with schizophrenia may lie in altered levels of dopamine receptor–interacting proteins.Arch Gen Psychiatry. 2003;60:311-319--></description><identifier>ISSN: 0003-990X</identifier><identifier>EISSN: 1538-3636</identifier><identifier>DOI: 10.1001/archpsyc.60.3.311</identifier><identifier>PMID: 12622665</identifier><identifier>CODEN: ARGPAQ</identifier><language>eng</language><publisher>Chicago, IL: American Medical Association</publisher><subject>Adult and adolescent clinical studies ; Animals ; Antipsychotic Agents - pharmacology ; Biological and medical sciences ; Bipolar Disorder - diagnosis ; Bipolar Disorder - metabolism ; Blotting, Western ; Cell Count ; Contractile Proteins - analysis ; Contractile Proteins - metabolism ; Depressive Disorder - diagnosis ; Depressive Disorder - metabolism ; Female ; Filamins ; Functional Laterality ; Haloperidol - pharmacology ; Humans ; Macaca mulatta ; Male ; Medical sciences ; Membrane Proteins - analysis ; Membrane Proteins - metabolism ; Microfilament Proteins - analysis ; Microfilament Proteins - metabolism ; Nerve Tissue Proteins - analysis ; Nerve Tissue Proteins - metabolism ; Neuroglia - drug effects ; Neuroglia - metabolism ; Neurons - drug effects ; Neurons - metabolism ; Prefrontal Cortex - chemistry ; Prefrontal Cortex - cytology ; Prefrontal Cortex - drug effects ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Receptors, Dopamine D1 - analysis ; Receptors, Dopamine D1 - drug effects ; Receptors, Dopamine D1 - metabolism ; Schizophrenia ; Schizophrenia - diagnosis ; Schizophrenia - metabolism ; Up-Regulation</subject><ispartof>Archives of general psychiatry, 2003-03, Vol.60 (3), p.311-319</ispartof><rights>2003 INIST-CNRS</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a388t-3504b6dda2b62c391ef462b22d5c4e3f6b669d39e602577681b4cc15a099a7b73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamapsychiatry/articlepdf/10.1001/archpsyc.60.3.311$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/archpsyc.60.3.311$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,780,784,3340,27924,27925,76489,76492</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14640004$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12622665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koh, Phil Ok</creatorcontrib><creatorcontrib>Bergson, Clare</creatorcontrib><creatorcontrib>Undie, Ashiwel S</creatorcontrib><creatorcontrib>Goldman-Rakic, Patricia S</creatorcontrib><creatorcontrib>Lidow, Michael S</creatorcontrib><title>Up-regulation of the D1 Dopamine Receptor–Interacting Protein, Calcyon, in Patients With Schizophrenia</title><title>Archives of general psychiatry</title><addtitle>Arch Gen Psychiatry</addtitle><description>BACKGROUND The dopamine hypothesis remains a prominent influence on research into the pathogenesis of schizophrenia, yet the presence of consistent schizophrenia-linked abnormalities in the presynaptic components of the dopamine system or in dopamine receptors still remains a matter of debate. The present study focuses on a recently recognized group of dopamine receptor–interacting proteins as possible novel sites of dysfunction in schizophrenia. Specifically, we examined whether the D1 dopamine receptor–interacting protein calcyon and the D2 dopamine receptor–interacting proteins filamin-A and spinophilin are affected in the dorsolateral prefrontal cortex of patients with schizophrenia. METHODS Slot blots of dorsolateral prefrontal cortical tissue were used to compare the levels of the 3 proteins of interest in control, schizophrenic, bipolar, and major depression groups (n = 15 per group). The nonschizophrenic psychiatric groups were included to determine the specificity of the detected abnormalities. RESULTS The dorsolateral prefrontal cortex in schizophrenic patients displayed nearly twice the normal levels of calcyon, whereas filamin-A and spinophilin levels were unaltered. Patients with bipolar disorder or major depression showed no changes in all 3 proteins examined. CONCLUSION Our findings provide the first evidence that abnormalities in the dopamine system of patients with schizophrenia may lie in altered levels of dopamine receptor–interacting proteins.Arch Gen Psychiatry. 2003;60:311-319--></description><subject>Adult and adolescent clinical studies</subject><subject>Animals</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Bipolar Disorder - diagnosis</subject><subject>Bipolar Disorder - metabolism</subject><subject>Blotting, Western</subject><subject>Cell Count</subject><subject>Contractile Proteins - analysis</subject><subject>Contractile Proteins - metabolism</subject><subject>Depressive Disorder - diagnosis</subject><subject>Depressive Disorder - metabolism</subject><subject>Female</subject><subject>Filamins</subject><subject>Functional Laterality</subject><subject>Haloperidol - pharmacology</subject><subject>Humans</subject><subject>Macaca mulatta</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Proteins - analysis</subject><subject>Membrane Proteins - metabolism</subject><subject>Microfilament Proteins - analysis</subject><subject>Microfilament Proteins - metabolism</subject><subject>Nerve Tissue Proteins - analysis</subject><subject>Nerve Tissue Proteins - metabolism</subject><subject>Neuroglia - drug effects</subject><subject>Neuroglia - metabolism</subject><subject>Neurons - drug effects</subject><subject>Neurons - metabolism</subject><subject>Prefrontal Cortex - chemistry</subject><subject>Prefrontal Cortex - cytology</subject><subject>Prefrontal Cortex - drug effects</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Receptors, Dopamine D1 - analysis</subject><subject>Receptors, Dopamine D1 - drug effects</subject><subject>Receptors, Dopamine D1 - metabolism</subject><subject>Schizophrenia</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenia - metabolism</subject><subject>Up-Regulation</subject><issn>0003-990X</issn><issn>1538-3636</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkc1u1DAURi0EotPCA3SDvIEVGfyTOMkSTaFUqkQFVLCzbpybxiixU9uzmK76DrwhT4KrmdKV79U937c4JuSUszVnjH-AYMYl7sxasbVcS86fkRWvZFNIJdVzsmKMyaJt2a8jchzj77yySomX5IgLJYRS1YqM10sR8GY7QbLeUT_QNCI94_TMLzBbh_QbGlySD3_v_1y4hAFMsu6GXgWf0Lr3dAOT2fk8WEevcgu6FOlPm0b63Yz2zi9jQGfhFXkxwBTx9eE9IdefP_3YfCkuv55fbD5eFiCbJhWyYmWn-h5Ep4SRLcehVKIToq9MiXJQnVJtL1tUTFR1rRrelcbwCljbQt3V8oS82_cuwd9uMSY922hwmsCh30ZdS5ZTlcgg34Mm-BgDDnoJdoaw05zpB736Ua9WTEud9ebMm0P5tpuxf0ocfGbg7QGAaGAaAjhj4xNXqjJ_Qpm50z0HM_y_ClaLppb_AMkTjl0</recordid><startdate>20030301</startdate><enddate>20030301</enddate><creator>Koh, Phil Ok</creator><creator>Bergson, Clare</creator><creator>Undie, Ashiwel S</creator><creator>Goldman-Rakic, Patricia S</creator><creator>Lidow, Michael S</creator><general>American Medical Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030301</creationdate><title>Up-regulation of the D1 Dopamine Receptor–Interacting Protein, Calcyon, in Patients With Schizophrenia</title><author>Koh, Phil Ok ; Bergson, Clare ; Undie, Ashiwel S ; Goldman-Rakic, Patricia S ; Lidow, Michael S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a388t-3504b6dda2b62c391ef462b22d5c4e3f6b669d39e602577681b4cc15a099a7b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Animals</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Bipolar Disorder - diagnosis</topic><topic>Bipolar Disorder - metabolism</topic><topic>Blotting, Western</topic><topic>Cell Count</topic><topic>Contractile Proteins - analysis</topic><topic>Contractile Proteins - metabolism</topic><topic>Depressive Disorder - diagnosis</topic><topic>Depressive Disorder - metabolism</topic><topic>Female</topic><topic>Filamins</topic><topic>Functional Laterality</topic><topic>Haloperidol - pharmacology</topic><topic>Humans</topic><topic>Macaca mulatta</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Proteins - analysis</topic><topic>Membrane Proteins - metabolism</topic><topic>Microfilament Proteins - analysis</topic><topic>Microfilament Proteins - metabolism</topic><topic>Nerve Tissue Proteins - analysis</topic><topic>Nerve Tissue Proteins - metabolism</topic><topic>Neuroglia - drug effects</topic><topic>Neuroglia - metabolism</topic><topic>Neurons - drug effects</topic><topic>Neurons - metabolism</topic><topic>Prefrontal Cortex - chemistry</topic><topic>Prefrontal Cortex - cytology</topic><topic>Prefrontal Cortex - drug effects</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Receptors, Dopamine D1 - analysis</topic><topic>Receptors, Dopamine D1 - drug effects</topic><topic>Receptors, Dopamine D1 - metabolism</topic><topic>Schizophrenia</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenia - metabolism</topic><topic>Up-Regulation</topic><toplevel>online_resources</toplevel><creatorcontrib>Koh, Phil Ok</creatorcontrib><creatorcontrib>Bergson, Clare</creatorcontrib><creatorcontrib>Undie, Ashiwel S</creatorcontrib><creatorcontrib>Goldman-Rakic, Patricia S</creatorcontrib><creatorcontrib>Lidow, Michael S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of general psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koh, Phil Ok</au><au>Bergson, Clare</au><au>Undie, Ashiwel S</au><au>Goldman-Rakic, Patricia S</au><au>Lidow, Michael S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Up-regulation of the D1 Dopamine Receptor–Interacting Protein, Calcyon, in Patients With Schizophrenia</atitle><jtitle>Archives of general psychiatry</jtitle><addtitle>Arch Gen Psychiatry</addtitle><date>2003-03-01</date><risdate>2003</risdate><volume>60</volume><issue>3</issue><spage>311</spage><epage>319</epage><pages>311-319</pages><issn>0003-990X</issn><eissn>1538-3636</eissn><coden>ARGPAQ</coden><abstract>BACKGROUND The dopamine hypothesis remains a prominent influence on research into the pathogenesis of schizophrenia, yet the presence of consistent schizophrenia-linked abnormalities in the presynaptic components of the dopamine system or in dopamine receptors still remains a matter of debate. The present study focuses on a recently recognized group of dopamine receptor–interacting proteins as possible novel sites of dysfunction in schizophrenia. Specifically, we examined whether the D1 dopamine receptor–interacting protein calcyon and the D2 dopamine receptor–interacting proteins filamin-A and spinophilin are affected in the dorsolateral prefrontal cortex of patients with schizophrenia. METHODS Slot blots of dorsolateral prefrontal cortical tissue were used to compare the levels of the 3 proteins of interest in control, schizophrenic, bipolar, and major depression groups (n = 15 per group). The nonschizophrenic psychiatric groups were included to determine the specificity of the detected abnormalities. RESULTS The dorsolateral prefrontal cortex in schizophrenic patients displayed nearly twice the normal levels of calcyon, whereas filamin-A and spinophilin levels were unaltered. Patients with bipolar disorder or major depression showed no changes in all 3 proteins examined. CONCLUSION Our findings provide the first evidence that abnormalities in the dopamine system of patients with schizophrenia may lie in altered levels of dopamine receptor–interacting proteins.Arch Gen Psychiatry. 2003;60:311-319--></abstract><cop>Chicago, IL</cop><pub>American Medical Association</pub><pmid>12622665</pmid><doi>10.1001/archpsyc.60.3.311</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-990X |
| ispartof | Archives of general psychiatry, 2003-03, Vol.60 (3), p.311-319 |
| issn | 0003-990X 1538-3636 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73076852 |
| source | MEDLINE; American Medical Association Journals |
| subjects | Adult and adolescent clinical studies Animals Antipsychotic Agents - pharmacology Biological and medical sciences Bipolar Disorder - diagnosis Bipolar Disorder - metabolism Blotting, Western Cell Count Contractile Proteins - analysis Contractile Proteins - metabolism Depressive Disorder - diagnosis Depressive Disorder - metabolism Female Filamins Functional Laterality Haloperidol - pharmacology Humans Macaca mulatta Male Medical sciences Membrane Proteins - analysis Membrane Proteins - metabolism Microfilament Proteins - analysis Microfilament Proteins - metabolism Nerve Tissue Proteins - analysis Nerve Tissue Proteins - metabolism Neuroglia - drug effects Neuroglia - metabolism Neurons - drug effects Neurons - metabolism Prefrontal Cortex - chemistry Prefrontal Cortex - cytology Prefrontal Cortex - drug effects Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychoses Receptors, Dopamine D1 - analysis Receptors, Dopamine D1 - drug effects Receptors, Dopamine D1 - metabolism Schizophrenia Schizophrenia - diagnosis Schizophrenia - metabolism Up-Regulation |
| title | Up-regulation of the D1 Dopamine Receptor–Interacting Protein, Calcyon, in Patients With Schizophrenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T13%3A40%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Up-regulation%20of%20the%20D1%20Dopamine%20Receptor%E2%80%93Interacting%20Protein,%20Calcyon,%20in%20Patients%20With%20Schizophrenia&rft.jtitle=Archives%20of%20general%20psychiatry&rft.au=Koh,%20Phil%20Ok&rft.date=2003-03-01&rft.volume=60&rft.issue=3&rft.spage=311&rft.epage=319&rft.pages=311-319&rft.issn=0003-990X&rft.eissn=1538-3636&rft.coden=ARGPAQ&rft_id=info:doi/10.1001/archpsyc.60.3.311&rft_dat=%3Cproquest_cross%3E73076852%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73076852&rft_id=info:pmid/12622665&rft_ama_id=207287&rfr_iscdi=true |